100 related articles for article (PubMed ID: 22357638)
1. Cost-effectiveness of fulvestrant 250 mg versus 500 mg in postmenopausal women with estrogen receptor-positive metastatic breast cancer and disease progression after antiestrogen therapy.
Newman MJ; Jones LT; Kraft JM; Lee AR; Lech GM; Farrell NM; Phantumvanit V; Edwards RA
J Oncol Pharm Pract; 2012 Dec; 18(4):394-401. PubMed ID: 22357638
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model.
Lux MP; Hartmann M; Jackisch C; Raab G; Schneeweiss A; Possinger K; Oyee J; Harbeck N
Breast Cancer Res Treat; 2009 Sep; 117(2):305-17. PubMed ID: 19130218
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
Safra T; Greenberg J; Ron IG; Ben-Yosef R; Inbar M; Sarid D; Yaal-Hahoshen N
Isr Med Assoc J; 2008 May; 10(5):339-43. PubMed ID: 18605354
[TBL] [Abstract][Full Text] [Related]
4. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
[TBL] [Abstract][Full Text] [Related]
5. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
[TBL] [Abstract][Full Text] [Related]
6. Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models.
Cope S; Ouwens MJ; Jansen JP; Schmid P
Value Health; 2013; 16(2):403-17. PubMed ID: 23538193
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
8. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
[TBL] [Abstract][Full Text] [Related]
9. Fulvestrant in postmenopausal women with advanced breast cancer.
Bross PF; Baird A; Chen G; Jee JM; Lostritto RT; Morse DE; Rosario LA; Williams GM; Yang P; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2003 Oct; 9(12):4309-17. PubMed ID: 14555500
[TBL] [Abstract][Full Text] [Related]
10. Fulvestrant ('Faslodex'): current and future role in breast cancer management.
Howell A
Crit Rev Oncol Hematol; 2006 Mar; 57(3):265-73. PubMed ID: 16473018
[TBL] [Abstract][Full Text] [Related]
11. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
Yardley DA; Burris HA; Clark BL; Shipley D; Rubin M; Barton J; Arrowsmith E; Hainsworth JD
Clin Breast Cancer; 2011 Jun; 11(3):146-52. PubMed ID: 21665134
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).
Pritchard KI; Rolski J; Papai Z; Mauriac L; Cardoso F; Chang J; Panasci L; Ianuli C; Kahan Z; Fukase K; Lindemann JP; Macpherson MP; Neven P
Breast Cancer Res Treat; 2010 Sep; 123(2):453-61. PubMed ID: 20632084
[TBL] [Abstract][Full Text] [Related]
13. Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.
Berrios K; Burum A; Jeong E; Zhong L
J Manag Care Spec Pharm; 2022 Nov; 28(11):1282-1291. PubMed ID: 36282933
[No Abstract] [Full Text] [Related]
14. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Di Leo A; Jerusalem G; Petruzelka L; Torres R; Bondarenko IN; Khasanov R; Verhoeven D; Pedrini JL; Smirnova I; Lichinitser MR; Pendergrass K; Garnett S; Lindemann JP; Sapunar F; Martin M
J Clin Oncol; 2010 Oct; 28(30):4594-600. PubMed ID: 20855825
[TBL] [Abstract][Full Text] [Related]
15. Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer From a US Payer Perspective.
Xie J; Hao Y; Zhou ZY; Qi CZ; De G; Glück S
Clin Breast Cancer; 2015 Oct; 15(5):e263-76. PubMed ID: 26048087
[TBL] [Abstract][Full Text] [Related]
16. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
[TBL] [Abstract][Full Text] [Related]
17. A good drug made better: the fulvestrant dose-response story.
Robertson JF; Lindemann J; Garnett S; Anderson E; Nicholson RI; Kuter I; Gee JM
Clin Breast Cancer; 2014 Dec; 14(6):381-9. PubMed ID: 25457991
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
Gradishar W
Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer.
Ding H; Fang L; Xin W; Tong Y; Zhou Q; Huang P
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28675545
[TBL] [Abstract][Full Text] [Related]
20. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
Vergote I; Robertson JF
Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
